source
- Roivant's brepocitinib cuts steroid use in non-infectious uveitis in Phase 3 trialsRoivant Sciences and its subsidiary Priovant reported that their TYK2/JAK inhibitor brepocitinib met all primary and secondary endpoints in two identical Phase 3 studies (Clarity‑1 and Clarity‑2) i…
- Georgiamune to ship preclinical solid tumor drug to Menarini in deal up to $1.1 billionGeorgiamune, a small biotech based in Maryland, announced that it will supply its preclinical solid tumor candidate to Menarini, a family‑owned pharmaceutical company in Italy. The agreement is st…